Fig. 6From: Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranosticsReprinted (adapted) with permission from Fan et al. [121]. (Copyright © 2021Fan et al. Journal of Nanobiotechnology published by BioMed Central). http://creativecommons.org/licenses/by/4.0/The application of MPDA@SPIO/SA-PEI/AFP-Fth nanocomplexes as an effective MR contrast agent in the early stage of HCC.Back to article page